‘Gold Card Fund’ adds a new drug formula “Sofosbuvier / Ves Patavir” can be used to treat all strains of the liver virus. Help save 56 million budget.
Stay on top of the news Press to follow the live news line.
On January 18, 64, Mr. Nimit Tianudom, National Health Security Committee Member And the director of the AIDS Access Foundation said that the National Health Security Committee (NHSO Board) has approved the addition of Sophos Bouvir / Wellpatavir. (Sofosbuvir / Velpatasvir) with a direct mechanism of action. In inhibiting the hepatitis C virus Can be used to treat all types of hepatitis C virus Good productivity and budget. When compared with the traditional treatment
By the National Core Drug List It has passed a resolution to include in the list of main drugs in order to be a benefit for all persons infected with hepatitis C who are in the treatment criteria by the NHSO, making the criteria for compensation for service fees, screening service And further confirmation of the hepatitis C virus for service units in 2 groups: 1. HIV-infected and 2. Substance users with injection.
“People who have been diagnosed with hepatitis C virus And still not receiving treatment Ask your doctor to find out how to be treated with this drug. As for those at risk of exposure to hepatitis C virus Especially people with HIV And injectable drug users who have not been screened Contact the hospital for a procedural screening. If infected will go into treatment Reduce cirrhosis Or liver cancer Which can be screened in Every community hospital, ”said Nimit.
Dr. Opaskarn Kawinpong, MD. Director-General of the Department of Disease Control said that hepatitis C is a silent threat to health. Because the infected in the early stages will not have symptoms Will appear when the disease progresses It causes cirrhosis and liver cancer, so people at risk of exposure to hepatitis C virus. Should be screened and brought into treatment as soon as possible.
In the past, the treatment of hepatitis C Dosage must match the species. Difficult and costly examination procedures The screening benefit is not yet comprehensive. Causing a large number of infected people to develop cirrhosis or liver cancer and death Therefore, when there is a new drug that is effective And was packed as a benefit Thus supporting access to treatment and screening at risk groups to find patients. Especially at risk groups before the disease progresses
Dr. Pisit Tangkitvanich, MD. President of the Hepatitis Association of Thailand said there are 3 steps to the treatment of people with hepatitis C: 1. Screening with anti-HCV test, especially at risk groups such as drug addicts by injection Patients who have previously received blood, etc.
2. Confirm that there is real infection by measuring the viral load in the blood by HCV RNA method.
And 3. If there is an indication that the patient needs to receive the drug Liver function and liver flexibility will be examined prior to administration. In the past, fibroccan technology was used and had to detect the strain of the hepatitis C virus (Genotype).
Currently, the need for examination has decreased. Because there is a hepatitis C drug that is effective for all strains It makes the treatment more convenient and accessible. The internist can give drugs to people infected with hepatitis C in the early stages. There is no need to refer to a specialist for liver disease that is currently not many. This is to distribute work for the hepatologists to take care of patients with severe disease.
Dr. Sakchai Kanjanawattana, secretary-general of NHSO, said that the Sophos Bouvier / Well Patasver It was studied by the Health Technology and Policy Evaluation Program (HITAP) that compared the budget with the current drug regimen.
In terms of drug costs and laboratory testing in 4,000 patients, it was found that the Sophosbuvir / Wellpatavir combination drug. Save 45.47 million baht on medication costs, save 11.12 million baht for laboratory testing, and 56.59 million baht, which can be used to increase care and access to treatment for patients and at risk groups. Prepare the systems To support the care
–
